Lessons to be learned from the Vioxx debacle.
Beller
George A
GA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D003257:Consumer Product Safety / Q000592:standards; D004345:Drug Industry; D004346:Drug Information Services; D006801:Humans; D033181:Information Dissemination / Q000379:methods*; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000209:etiology* / Q000517:prevention & control*; D011358:Product Surveillance, Postmarketing / Q000379:methods* / Q000592:standards; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib